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A. A. Soliman, MD1,2, R. Csorba, MD1,3, A. Ullrich, MD1,
P. Tsikouras, MD1, W. Rath, MD4, and G.-F. von Tempelhoff, MD1
Venous thromboembolic events (VTEs) are life-threatening
complications in patients with cancer and remain the second
most common cause of death in hospitalized patients with can-
cer, after death from cancer itself.1 Patients with breast cancer,
however, are considered to be at relatively low risk of develop-
ing VTE.2 In a cohort of 108 255 patients with breast cancer,
the 1- and 2-year cumulative incidence of VTE was estimated
to be 0.9% and 1.2%, respectively.3 Both chemotherapy in gen-
eral and the agent used in particular were found to increase the
risk of developing VTE. A systematic screening for thrombosis
during anthracycline-based regimens in adjuvant settings
revealed a higher VTE (10%)4 rate when compared to the con-
ventional cyclophosphamide methotrexate fluorouracil therapy
(5.4%).5 The route of application of chemotherapeutic agents
represents another high risk factor for the development of VTE.
Catheter-related thrombosis (CRT) involves 70% to 80% of all
upper extremity thrombotic events and represents about 10% of
all cases of VTE in patients with cancer receiving chemother-
apy.6 The role of acquired thrombophilia such as the induction
of antiphospholipid antibodies (aPL-abs) and lupus anticoagu-
lant (LAC) in the pathogenesis of VTE in patients with breast
cancer has been reported but is still a matter of debate.
In a prospective, case-controlled study, we assessed the rate of
symptomatic VTE in primary nonmetastatic, patients with breast
cancerwho received adjuvant anthracycline-based chemotherapy
regimens postoperatively via an intravenous port-catheter device
(Hickman port, Celsite1Access Port venous low-profile compo-
site access ports with titanium chamber, Braun Melsungen AG,
Germany). The standard combination administered every 3
weeks and for 6-treatment cycles was as follows: cyclophospha-
mide 500 mg/m2, doxorubicin/epirubicin 15 mg/m2, and flurour-
acil 1000mg/m.2 Prior to primary surgery and eachof the 6 cycles
of chemotherapy, laboratory tests for anticardiolipin antibodies
(aCL-ab; immunoglobulin [Ig]G-, IgM-enzyme-linked immuno-
sorbent assay [ELISA] >15 U/mL), LAC (partial thromboplastin
time ratio > 1.2), resistance to activated protein C (APC, Coatest;
Chromogenix, Mo¨lndal, Sweden; APC ratio < 2.0), and D-dimer
(ELISA > 500 mg/L) were performed. None of the patients
received anticoagulants unless thrombosis was confirmed. Con-
comitantly, clinical signs for thrombosis were assessed, namely,
increasing girth, marked edema, vague pain, and redness in the
corresponding upper limb. The collected data were tabulated and
analyzed using PSPP-project version 0.7.9, released February
2012.
Over a period of 1.5 years, 42 patients with breast cancer
(age: 60.6+ 7.5 years) were recruited; 49 age-matched healthy
women served as controls (age: 59.0+ 11.2 years; P ¼ .41).
In the study period, 7.2% of the patients with breast cancer
(n ¼ 3) developed symptomatic VTE, which were all localized
in the subclavian vein at the side of the port-catheter. All of
them occurred after the first chemotherapy cycle and were pro-
ven by contrast phlebography. Low-molecular-weight heparin
at therapeutic dose was initiated and continued until removal
of the device after the sixth cycle of chemotherapy. Sympto-
matic thrombosis of the pelvic veins, lower extremities, or in
other regions was not detected in any of the patients during the
1 Department of Obstetrics and Gynecology, City Hospital of Aschaffenburg,
Aschaffenburg, Germany
2Department of Obstetrics and Gynecology, University of Alexandria,
Alexandria, Egypt
3 Department of Obstetrics and Gynecology, University of Debrecen,
Debrecen, Hungary
4Department of Obstetrics and Gynecology, University RWTH Aachen,
Aachen, Germany
Corresponding Author:
G.-F. von Tempelhoff, MD, Department of Obstetrics and Gynecology, City
Hospital of Aschaffenburg, Hospital of Aschaffenburg, Am Hasenkopf, Aschaf-
fenburg 63739, Germany.
Email: G-F.von.tempelhoff@gmx.de
Clinical and Applied
Thrombosis/Hemostasis
2014, Vol. 20(3) 338-340
ª The Author(s) 2014
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1076029613508598
cat.sagepub.com
study period. Test results for aCL-ab (Figure 1A and B) and
LAC were negative in all of the patients, prior to surgery, prior
to the start of chemotherapy, and prior to each cycle of
chemotherapy. In one of the controls, however, aCL-ab was
elevated, but her medical history was uneventful, and there
were no clinical signs of thrombosis.
Mean D-dimer concentrations in patients with breast cancer
prior to surgerywere elevated (but not above the cutoff level) com-
pared to the concentrationsof thehealthyvolunteers (102+187vs
37+ 21 mg/L; P < .001); however, in 1 patient the D-dimer level
crossed the cutoff of 500 mg/L (970 mg/L) prior to chemotherapy
and remained high (930 mg/L) throughout the follow-up without
evidence of thrombosis.During chemotherapy,meanD-dimer con-
centrations remained unchanged in all of the patients. We noted
elevated D-dimer concentrations up to 620 and 760 mg/L, respec-
tively, in only 2 patients, without evidence of thrombosis.
None of the patients included in the present study had
elevated aPL-absat the time of primary diagnosis of breast,
and we did not detect any increase in aCL-ab or LAC con-
centrations in the follow-up during the chemotherapy cycles.
We therefore assume that the induction of aCL-ab or LAC—in
the sense of an acquired thrombophilia—is an infrequent phe-
nomenon in patients with breast cancer receiving standard
anthracycline-based chemotherapy.
The 7.2% incidence of CRT in our cohort is comparable to
that described in 1 study6 but contrary to others.7,8 Zuckerman
et al reported that 22% of the patients presenting with malignan-
cies in their cohort showed elevated aCL-ab concentrations,
compared with 3% in the control group without malignancies.
Moreover, the aCL-ab-positive patients had a significantly
higher rate of VTE than aCL-ab-negative patients. Interestingly,
the levels of aCL-ab decreased after successful treatment in 4
patients who remained free of thrombotic events thereafter.7
In a systematic review, Go´mez-Puerta et al concluded that the
increase in aCL-ab occurs in a wide range of different malignan-
cies and that they decrease in more than one-third of the patients
after cancer treatment.8 The APC resistance, either acquired or
inherited (factor V Leiden mutation), was also incriminated as
a possible cause ofVTE in patientswith cancer. Haim et al found
that the prevalence of acquired functional APC resistance was
significantly higher in patientswith cancerwho developedVTE.
They concluded that resistance to APC is a risk factor for VTE
and that acquired functional APC resistance is a common find-
ing in patients with cancer having venous thromboembolism
while the factor V Leiden mutation was unusual.9 These results
are contradictory to our findings. We observed that none of our
patients developed symptomatic VTE elsewhere apart from
CRT, and this made us to believe that most likely the mechan-
isms inducing CRT are different from those causing pelvic or
lower extremities thrombosis; therefore, the coagulation tests
as used in this study may be inappropriate to predict CRT.
Nijziel et al reported an increased resistance to APC in
56 patients with node-positive breast cancer 1 year or more
after chemotherapy in comparison with 28 healthy control par-
ticipants.10 In our cohort, we could not find any elevation in
APC resistance before and during chemotherapy both in
patients affected with VTE and those who were not. It is worth
mentioning that no other breast cancer study relating to the
course of functional acquired thrombophilia (APC resistance
and aPL-ab) during chemotherapy considering the develop-
ment of VTE has been published yet.
From our results and through comparing them to the pub-
lished relevant literature, we conclude that an increase in
aCL-ab, LAC, hence antiphospholipid syndrome, and functional
resistance to APC as well are infrequent events in patients with
breast cancer receiving adjuvant anthracycline-containing
Figure 1. A, Box plot showing the aCL-ab IgG levels before the breast operation and before each of the treatment cycles. Dots: outliers. B, A
box plot showing the aCL-ab IgM levels before the breast operation and before each of the treatment cycles. Dots: outliers. aCL-ab indicates
anticardiolipin antibody; Ig, immunoglobulin.
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chemotherapy combination, even in those patients who devel-
oped port-catheter thrombosis.
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